Sunitinib is approved for the treatment of gastrointestinal stromal tumors (GIST) in adults whose tumors continued to grow despite receiving the drug imatinib. However, sunitinib has not yet been assessed in children with advanced GIST. The purpose of this study is to evaluate the safety and effectiveness of sunitinib in patients with advanced GIST who are under 21 years of age.
Sunitinib inhibits the development of blood vessels that tumors need to grow and spread. It is a pill that is taken orally (by mouth).